A major challenge in the field of neuroscience is to link behavior with specific neuronal circuitries and cellular events. One way of facing this challenge is to identify unique cellular markers and thus have the ability to, through various mouse genetics tools, mimic, manipulate and control various aspects of neuronal activity to decipher their correlation to behavior. The Vesicular Glutamate Transporter 2 (VGLUT2) packages glutamate into presynaptic vesicles for axonal terminal release. In this thesis, VGLUT2 was used to specifically target cell populations within the basal ganglia of mice with the purpose of investigating its connectivity, function and involvement in behavior. The motor and limbic loops of the basal ganglia are important for processing of voluntary movement and emotions. During such physiological events, dopamine plays a central role in modulating the activity of these systems. The brain reward system is mainly formed by dopamine projections from the ventral tegmental area (VTA) to the ventral striatum. Certain dopamine neurons within the VTA exhibit the ability to co-release dopamine and glutamate. In paper I, glutamate and dopamine co-release was targeted and our results demonstrate that the absence of VGLUT2 in dopamine neurons leads to perturbations of reward consumption and reward-associated memory, probably due to reduced DA release observed in the striatum as detected by in vivo chronoamperometry. In papers II and IV, VGLUT2 in a specific subpopulation within the subthalamic nucleus (STN) was identified and targeted. Based on the described role of the STN in movement control, we hypothesized that the mice would be hyperlocomotive. As shown in paper II, this was indeed the case. In paper IV, a putative reward-related phenotype was approached and we could show reduced operant-self administration of sugar and altered dopamine release levels suggesting a role for the STN in reward processes. In paper III, we investigated and identified age- and sex-dimorphisms in dopamine kinetics in the dorsal striatum of one of the most commonly used mouse lines worldwide, the C57/Bl6J. Our results point to the importance of taking these dimorphisms into account when utilizing the C57/Bl6J strain as model for neurological and neuropsychiatric disorders.

In patients with Parkinson’s disease (PD), the molecularly misfolded form of α-synuclein was recently identified in cutaneous autonomic nerve fibers which displayed increased accumulation even in early disease stages. However, the underlying mechanisms of synucleinopathic nerve damage and its implication for brain pathology in later life remain to be elucidated. To date, specific diagnostic tools to evaluate small fiber pathology and to discriminate neurodegenerative proteinopathies are rare. Recently, research has indicated that deposition of α-synuclein in cutaneous nerve fibers quantified via immunohistochemistry in superficial skin biopsies might be a valid marker of PD which could facilitate early diagnosis and monitoring of disease progression. However, lack of standardization of techniques to quantify neural α-synuclein deposition limits their utility in clinical practice. Additional challenges include the identification of potential distinct morphological patterns of intraneural α-synuclein deposition among synucleinopathies to facilitate diagnostic discrimination and determining the degree to which structural damage relates to dysfunction of nerve fibers targeted by α-synuclein. Answering these questions might improve our understanding of the pathophysiological role of small fiber neuropathy in Parkinson’s disease, help identify new treatment targets, and facilitate assessment of response to neuroprotective treatment.

Introdução: A fisiopatologia da doença de Parkinson está associada a lesões por estresse oxidativo/nitrosativo. O ferro encontra-se acumulado na substância negra (SN) de pacientes com DP e está relacionado com esse dano através das espécies reagentes de oxigênio (EROs) e de nitrogênio (ERNs) na reação de Fenton. EROs e ERNs são produzidas normalmente em processos celulares e inflamatórios, e controladas por sistemas antioxidantes. Objetivo: Avaliar níveis periféricos de ferro em pacientes com DP para determinar se acúmulo na SN está relacionado com níveis elevados no sangue. Determinar biomarcadores periféricos confiáveis de estresse oxidativo/nitrosativo Métodos: Selecionados 40 pacientes com DP e 46 indivíduos controles para comparar níveis séricos de ferro, ferritina e transferrina, e de biomarcadores de estresse oxidativo/nitrosativo: superóxido dismutase (SOD), catalase, óxido nítrico (NOx), substâncias reativas ao ácido tiobarbitúrico (TBARS), tióis não-proteicos, “advanced oxidation protein products” (AOPP), “ferric reducing ability of plasma” (FRAP), NTPDases, ecto-5’-nucleotidase, adenosina deaminase (ADA), mieloperoxidase, albumina modificada pela isquemia (IMA) e vitamina C. Resultados: Níveis de ferro estavam diminuídos em pacientes com DP, enquanto ferritina e transferrina não mostraram diferença. Os biomarcadores de estresse oxidativo como TBARS, AOPP, NTPDases, IMA, mieloperoxidase, FRAP, vitamina C e tiois não-proteicos encontraram-se significativamente aumentados na DP. SOD, catalase, ecto-5’-nucleotidase não foram diferentes entre os grupos e os marcadores NOx e ADA foram significativamente aumentados nos controles. Nenhuma correlação foi encontrada entre os biomarcadores e dados sociodemográficos e de características da doença. Conclusão: Níveis plasmáticos de ferro encontram-se diminuídos em pacientes com DP comparados com controles saudáveis. Os biomarcadores TBARS, AOPP, NTPDases, IMA e mieloperoxidase mostraram-se confiáveis para lesão oxidativa, enquanto tióis não-proteicos, FRAP e vitamina C demonstram diminuição da capacidade antioxidante na DP. / Background: Parkinson’s disease (PD) pathophysiology is associated with oxidative/nitrosative stress damage. Iron accumulates in the substantia nigra (SN) of PD patients and is related to this damage along with oxygen and nitrogen reactive species (ROS, RNS) through Fenton reaction. ROS and RNS are normally produced in cell and inflammatory processes, controlled by antioxidant systems. Objective: To determine peripheral levels of iron, ferritin and transferrin in PD patients to evaluate whether iron accumulation in the SN could be related to serum levels. To determine reliable peripheral biomarkers of oxidative/nitrative stress. Methods: Forty PD patients and 46 controls were selected to compared serum levels of iron, ferritin, transferrin and oxidative/nitrative stress biomarkers: superoxide dismutase (SOD), catalase, nitric oxide (NOx), thiobarbituric acid reactive substances (TBARS), non-protein thiols, advanced oxidation protein products (AOPP), ferric reducing ability of plasma (FRAP), NTPDases, ecto-5’-nucleotidase, adenosine deaminase (ADA), myeloperoxidase, ischemic-modified albumin (IMA) and vitamin C. Results: Iron levels were decreased in patients with PD, while ferritin and transferrin were not different. Oxidative stress biomarkers, TBARS, AOPP, NTPDases, IMA, myeloperoxidase, FRAP, vitamin C and non-proteic thiols were significantly higher in PD. SOD, catalase, ecto-5’-nucleotidase were not different between the groups and biomarkers NOx and ADA were significantly increased in the controls. No correlation was found between biomarkers and sociodemographic and disease data. Conclusion: Plasmatic levels of iron are decreased in patients with PD compared to healthy controls. Biomarkers TBARS, AOPP, NTPDases, IMA and myeloperoxidase presented as reliable to measure oxidative/nitrative damage, while non-proteic thiols, FRAP and vitamin C show a decrease in the antioxidant capacity in PD.

Made available in DSpace on 2014-06-11T19:22:51Z (GMT). No. of bitstreams: 0 Previous issue date: 2009-08-06Bitstream added on 2014-06-13T19:49:08Z : No. of bitstreams: 1 arantes_lm_me_rcla.pdf: 491035 bytes, checksum: 9c4960c1f7c34e4bc86cddd4bb744ce3 (MD5) / Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) / O presente estudo teve como objetivo analisar o efeito do treinamento de força e potência na curva força-tempo isométrica e na ativação muscular em idosos com doença de Parkinson (DP). A amostra final foi composta por 25 participantes de ambos os gêneros (n=8 – grupo controle (GC); n=8 – grupo de força (GF); n=9 – grupo de potência (GP). Os grupos GF e GP realizaram treinamento com pesos, durante oito semanas, com especificidade para desenvolvimento de força ou potência musculares, respectivamente. O grupo controle (GC), composto por idosos com DP, realizou apenas o protocolo de avaliação pré e pós oito semanas. Os participantes realizaram consecutivamente: a) avaliação da Curva força-Tempo isométrica e da atividade eletromiográfica; b) início do protocolo de treinamento para os GF e GP; c) re-avaliação ao término do protocolo de treinamento de força e de potência. Para a análise dos dados foi utilizada estatística descritiva (média e desvio-padrão) e ANOVA two-way para medidas repetidas em todas as variáveis com nível de significância de p<0,05. Os resultados apontaram interações significativas (p<0,05) em contração voluntária máxima (CVM), taxa de desenvolvimento de força (TDF) no intervalo de tempo de 0-50ms e ativação muscular (iEMG) do músculo vasto lateral. Não foram encontradas interações significativas (p>0,05) na TDF nos intervalos de tempo 0-100; 0-150 e 0-200ms, TDFpico, impulso contrátil e ativação muscular (iEMG) dos vastos lateral e medial, nos intervalos de tempo 0-50; 0-100; 0-150 e 0-200ms, como também, na ativação do músculo vasto medial no momento da contração voluntária máxima. Portanto, conclui-se que o treinamento com pesos (força e potência) é capaz de aumentar a contração voluntária máxima, contudo o protocolo de potência parece trazer maiores benefícios; a capacidade dos idosos com DP de gerar... / The purpose of this study was to analyze the effect of strength and power training on isometric force-time curve and muscular activation in elderly individuals with Parkinson’s disease (PD). The initial sample was composed by 25 participants of both gender (n=8 – control group (CG); n=8 – strength group (SG); n=9 – power group (PG). Both group, SG and PG, participated of resistance training for eight weeks with specificity for development of strength and muscular power, respectively. The CG, with Parkinson’s disease, participated only of evaluation protocol, before and after eight weeks. Participants performed consecutively: a) evaluation of isometric force-time curve and muscular activation; b) start the resistance training protocol for SG and PG; c) revaluation of isometric force-time curve and muscular activation. For the data analysis it was used the descriptive statistics (mean and standard deviation) and two-way ANOVA for repeated measurements of all variables. The level of significance adopted was p<0.05. The results pointed significant interactions (p<0.05) in maximum voluntary contraction (MVC), rate of force development (RFD) in time interval of 0–50 and integrated EMG of vastus lateralis (iEMG VL). No significant interactions (p>0.05) were found in rate of force development (RFD) in time intervals of 0–100; 150; and 200 ms, peak of rate of force development (RFD peak), contractile impulse (CI) and integrated EMG of vastus lateralis and vastus medialis in time intervals of 0–50, 100, 150, and 200 ms as well in integrated EMG of vastus medialis at the same moment of MVC. In conclusion, the resistance training (strength and power) it is capable to increase the MVC, however the power training protocol seems to be more beneficial; the PD seniors’ capacity to generate fast force (TDF) in the first ones 50ms increase after eight weeks of power training... (Complete abstract click electronic access below)

Introdução: A fisiopatologia da doença de Parkinson está associada a lesões por estresse oxidativo/nitrosativo. O ferro encontra-se acumulado na substância negra (SN) de pacientes com DP e está relacionado com esse dano através das espécies reagentes de oxigênio (EROs) e de nitrogênio (ERNs) na reação de Fenton. EROs e ERNs são produzidas normalmente em processos celulares e inflamatórios, e controladas por sistemas antioxidantes. Objetivo: Avaliar níveis periféricos de ferro em pacientes com DP para determinar se acúmulo na SN está relacionado com níveis elevados no sangue. Determinar biomarcadores periféricos confiáveis de estresse oxidativo/nitrosativo Métodos: Selecionados 40 pacientes com DP e 46 indivíduos controles para comparar níveis séricos de ferro, ferritina e transferrina, e de biomarcadores de estresse oxidativo/nitrosativo: superóxido dismutase (SOD), catalase, óxido nítrico (NOx), substâncias reativas ao ácido tiobarbitúrico (TBARS), tióis não-proteicos, “advanced oxidation protein products” (AOPP), “ferric reducing ability of plasma” (FRAP), NTPDases, ecto-5’-nucleotidase, adenosina deaminase (ADA), mieloperoxidase, albumina modificada pela isquemia (IMA) e vitamina C. Resultados: Níveis de ferro estavam diminuídos em pacientes com DP, enquanto ferritina e transferrina não mostraram diferença. Os biomarcadores de estresse oxidativo como TBARS, AOPP, NTPDases, IMA, mieloperoxidase, FRAP, vitamina C e tiois não-proteicos encontraram-se significativamente aumentados na DP. SOD, catalase, ecto-5’-nucleotidase não foram diferentes entre os grupos e os marcadores NOx e ADA foram significativamente aumentados nos controles. Nenhuma correlação foi encontrada entre os biomarcadores e dados sociodemográficos e de características da doença. Conclusão: Níveis plasmáticos de ferro encontram-se diminuídos em pacientes com DP comparados com controles saudáveis. Os biomarcadores TBARS, AOPP, NTPDases, IMA e mieloperoxidase mostraram-se confiáveis para lesão oxidativa, enquanto tióis não-proteicos, FRAP e vitamina C demonstram diminuição da capacidade antioxidante na DP. / Background: Parkinson’s disease (PD) pathophysiology is associated with oxidative/nitrosative stress damage. Iron accumulates in the substantia nigra (SN) of PD patients and is related to this damage along with oxygen and nitrogen reactive species (ROS, RNS) through Fenton reaction. ROS and RNS are normally produced in cell and inflammatory processes, controlled by antioxidant systems. Objective: To determine peripheral levels of iron, ferritin and transferrin in PD patients to evaluate whether iron accumulation in the SN could be related to serum levels. To determine reliable peripheral biomarkers of oxidative/nitrative stress. Methods: Forty PD patients and 46 controls were selected to compared serum levels of iron, ferritin, transferrin and oxidative/nitrative stress biomarkers: superoxide dismutase (SOD), catalase, nitric oxide (NOx), thiobarbituric acid reactive substances (TBARS), non-protein thiols, advanced oxidation protein products (AOPP), ferric reducing ability of plasma (FRAP), NTPDases, ecto-5’-nucleotidase, adenosine deaminase (ADA), myeloperoxidase, ischemic-modified albumin (IMA) and vitamin C. Results: Iron levels were decreased in patients with PD, while ferritin and transferrin were not different. Oxidative stress biomarkers, TBARS, AOPP, NTPDases, IMA, myeloperoxidase, FRAP, vitamin C and non-proteic thiols were significantly higher in PD. SOD, catalase, ecto-5’-nucleotidase were not different between the groups and biomarkers NOx and ADA were significantly increased in the controls. No correlation was found between biomarkers and sociodemographic and disease data. Conclusion: Plasmatic levels of iron are decreased in patients with PD compared to healthy controls. Biomarkers TBARS, AOPP, NTPDases, IMA and myeloperoxidase presented as reliable to measure oxidative/nitrative damage, while non-proteic thiols, FRAP and vitamin C show a decrease in the antioxidant capacity in PD.

Introdução: A fisiopatologia da doença de Parkinson está associada a lesões por estresse oxidativo/nitrosativo. O ferro encontra-se acumulado na substância negra (SN) de pacientes com DP e está relacionado com esse dano através das espécies reagentes de oxigênio (EROs) e de nitrogênio (ERNs) na reação de Fenton. EROs e ERNs são produzidas normalmente em processos celulares e inflamatórios, e controladas por sistemas antioxidantes. Objetivo: Avaliar níveis periféricos de ferro em pacientes com DP para determinar se acúmulo na SN está relacionado com níveis elevados no sangue. Determinar biomarcadores periféricos confiáveis de estresse oxidativo/nitrosativo Métodos: Selecionados 40 pacientes com DP e 46 indivíduos controles para comparar níveis séricos de ferro, ferritina e transferrina, e de biomarcadores de estresse oxidativo/nitrosativo: superóxido dismutase (SOD), catalase, óxido nítrico (NOx), substâncias reativas ao ácido tiobarbitúrico (TBARS), tióis não-proteicos, “advanced oxidation protein products” (AOPP), “ferric reducing ability of plasma” (FRAP), NTPDases, ecto-5’-nucleotidase, adenosina deaminase (ADA), mieloperoxidase, albumina modificada pela isquemia (IMA) e vitamina C. Resultados: Níveis de ferro estavam diminuídos em pacientes com DP, enquanto ferritina e transferrina não mostraram diferença. Os biomarcadores de estresse oxidativo como TBARS, AOPP, NTPDases, IMA, mieloperoxidase, FRAP, vitamina C e tiois não-proteicos encontraram-se significativamente aumentados na DP. SOD, catalase, ecto-5’-nucleotidase não foram diferentes entre os grupos e os marcadores NOx e ADA foram significativamente aumentados nos controles. Nenhuma correlação foi encontrada entre os biomarcadores e dados sociodemográficos e de características da doença. Conclusão: Níveis plasmáticos de ferro encontram-se diminuídos em pacientes com DP comparados com controles saudáveis. Os biomarcadores TBARS, AOPP, NTPDases, IMA e mieloperoxidase mostraram-se confiáveis para lesão oxidativa, enquanto tióis não-proteicos, FRAP e vitamina C demonstram diminuição da capacidade antioxidante na DP. / Background: Parkinson’s disease (PD) pathophysiology is associated with oxidative/nitrosative stress damage. Iron accumulates in the substantia nigra (SN) of PD patients and is related to this damage along with oxygen and nitrogen reactive species (ROS, RNS) through Fenton reaction. ROS and RNS are normally produced in cell and inflammatory processes, controlled by antioxidant systems. Objective: To determine peripheral levels of iron, ferritin and transferrin in PD patients to evaluate whether iron accumulation in the SN could be related to serum levels. To determine reliable peripheral biomarkers of oxidative/nitrative stress. Methods: Forty PD patients and 46 controls were selected to compared serum levels of iron, ferritin, transferrin and oxidative/nitrative stress biomarkers: superoxide dismutase (SOD), catalase, nitric oxide (NOx), thiobarbituric acid reactive substances (TBARS), non-protein thiols, advanced oxidation protein products (AOPP), ferric reducing ability of plasma (FRAP), NTPDases, ecto-5’-nucleotidase, adenosine deaminase (ADA), myeloperoxidase, ischemic-modified albumin (IMA) and vitamin C. Results: Iron levels were decreased in patients with PD, while ferritin and transferrin were not different. Oxidative stress biomarkers, TBARS, AOPP, NTPDases, IMA, myeloperoxidase, FRAP, vitamin C and non-proteic thiols were significantly higher in PD. SOD, catalase, ecto-5’-nucleotidase were not different between the groups and biomarkers NOx and ADA were significantly increased in the controls. No correlation was found between biomarkers and sociodemographic and disease data. Conclusion: Plasmatic levels of iron are decreased in patients with PD compared to healthy controls. Biomarkers TBARS, AOPP, NTPDases, IMA and myeloperoxidase presented as reliable to measure oxidative/nitrative damage, while non-proteic thiols, FRAP and vitamin C show a decrease in the antioxidant capacity in PD.

Les processus compensatoires qui accompagnent les atteintes du système dopaminergique (DA-ergic) nigrostrié illustrent les capacités adaptatives du cerveau adulte. Cette neuroplasticité permet le maintien de la transmission dopaminergique pendant un certain temps de sorte que les symptômes moteurs cardinaux de la Maladie de Parkinson (MP), qui se caractérise par une dégénérescence progressive des neurones DA-ergiques de la substantia nigra (SN), ne se manifestent qu'après une perte neuronale très importante. De ce fait, le diagnostic présymptomatique est une question cruciale pour le développement de traitements neuroprotecteurs. Un autre exemple de neuroplasticité est illustré par la production de nouveaux neurones dans le cerveau adulte (neurogenèse adulte). Cette neurogenèse s’observe principalement dans deux zones: le continuum zone sous-ventriculaire (SVZ)-bulbe olfactif (OB) et le gyrus denté (DG) de l'hippocampe, et se trouve altérée chez les patients parkinsoniens. Ces dernières années, le traitement chirurgical par la stimulation à haute fréquence (SHF) du noyau sous-thalamique (NST) s'est avéré être une option thérapeutique très efficace pour ces patients. Dans ce contexte, mon travail de thèse a été axé sur l’étude de la neuroplasticité dans différents modèles de la maladie de Parkinson et de son traitement avec les objectifs principaux: 1) Développer un modèle de MP présymptomatique; 2) étudier les mécanismes compensatoires impliquant le système nigrostrié; 3) Déterminer les effets de la SHF-NST sur la neurogenèse adulte dans la SVZ-OB et le DG.Dans la première étude, nous avons développé des modèles expérimentaux de la MP à différents stades, basés sur l’administration de MPTP chez la souris. Nous avons montré que le passage du stade avancé présymptomatique au stade symptomatique précoce correspondant au seuil d’atteinte des systèmes DA-ergiques associé à l’apparition des déficits moteurs, se caractérise par : (a) une diminution de DA dans les terminaisons striatales épargnées par la lésion; (b) une augmentation de DA et d’expression de la tyrosine hydroxylase dans les cellules de la SN; (c) une augmentation du renouvellement de la DA dans le striatum et une augmentation moindre dans la SN.La deuxième étude est basée sur un modèle de lésion DA-ergique extensive par injection intranigrale de 6-hydroxydopamine chez le rat, imitant les stades tardifs de la MP. Nous avons étudié séparément les étapes de prolifération et de survie des nouvelles cellules sur des animaux non lésés et des animaux lésés avec ou sans SHF subchronique (8 jours) du NST. Nous avons pu montrer une régulation spécifique des étapes de prolifération et de survie suite à la lésion dopaminergique, et des effets stimulateurs de la SHF du NST sur la survie des cellules néoformées, suggérant un effet neuroprotecteur de ce traitement. / The compensatory processes that accompany a lesion of the nigrostriatal dopaminergic (DA-ergic) system serve to maintain its function and illustrate adult brain neuroplasticity. The typical motor symptoms of Parkinson’s diseases (PD), characterized by progressive degeneration of DA-ergic neurons of substantia nigra (SN), appear only after substantial neuronal loss. Therefore presymptomatic diagnosis is a crucial issue for future neuroprotective therapies. Another good manifestation of neuroplasticity is adult neurogenesis, known to persist in two areas: the subventricular zone (SVZ) – the olfactory bulb (OB) continuum, and the dentate gyrus (DG) of the hippocampus, and to be altered in PD. In recent years, the surgical treatment by high frequency stimulation (HFS) of the subthalamic nucleus (STN) has proven to be an efficient therapeutic option for PD patients. In this context, my PhD work was focused on neuroplasticity under the functional deficiency of the nigrostriatal DA-ergic system (parkinsonism) and its treatment with the following main objectives: 1 - Develop a model of presymptomatic parkinsonism; 2 - study compensatory mechanisms in nigrostriatal system; 3 - Characterize the effects of subchronic STN HFS on adult neurogenesis. In the first part, we have developed models of presymptomatic parkinsonism based on MPTP administration in mice, as defined by sub-threshold DA depletion and degeneration of DA-ergic axons in the striatum followed by a loss of DA-ergic cell bodies in the SN (advanced presymptomatic stage). In the early symptomatic stage, these parameters reach a threshold that is associated with the appearance of motor deficiency. We have shown that the transition from the advanced presymptomatic stage to the early symptomatic stage is characterized by: (a) a decrease of DA content in surviving DA-ergic axons in the striatum; (b) an increase of DA content and TH-expression in surviving neuronal cell bodies in the SN; (c) an increase of DA turnover in the striatum and much less increase in the SN. The last part of my work is based on extensive DA lesion in rats, using intranigral 6-hydroxydopamine injection mimicking late PD stages, to determine a possible effect of STN-HFS on adult neurogenesis. We have completed series of animals with DA lesion either sham implanted or subsequently treated for 8 days by STN-HFS to be compared with unlesioned rats, and studied selective phases of neurogenesis: proliferation and survival. This study demonstrates selective regulation of cell proliferation and survival following DA depletion and provides the first evidence that prolonged STN-HFS might have a neuroprotective action as shown by the selective increase in survival of newly formed cells following this treatment.

In patients with Parkinson’s disease (PD), the molecularly misfolded form of α-synuclein was recently identified in cutaneous autonomic nerve fibers which displayed increased accumulation even in early disease stages. However, the underlying mechanisms of synucleinopathic nerve damage and its implication for brain pathology in later life remain to be elucidated. To date, specific diagnostic tools to evaluate small fiber pathology and to discriminate neurodegenerative proteinopathies are rare. Recently, research has indicated that deposition of α-synuclein in cutaneous nerve fibers quantified via immunohistochemistry in superficial skin biopsies might be a valid marker of PD which could facilitate early diagnosis and monitoring of disease progression. However, lack of standardization of techniques to quantify neural α-synuclein deposition limits their utility in clinical practice. Additional challenges include the identification of potential distinct morphological patterns of intraneural α-synuclein deposition among synucleinopathies to facilitate diagnostic discrimination and determining the degree to which structural damage relates to dysfunction of nerve fibers targeted by α-synuclein. Answering these questions might improve our understanding of the pathophysiological role of small fiber neuropathy in Parkinson’s disease, help identify new treatment targets, and facilitate assessment of response to neuroprotective treatment.

Background: In Parkinson’s disease (PD), alpha-synuclein accumulation in cutaneous autonomic pilomotor and sudomotor nerve fibers has been linked to autonomic nervous system disturbances even in the early stages of the disease. This study aims to assess the association between alpha-synuclein-mediated structural autonomic nerve fiber damage and function in PD, elucidate the role of neuropathy progression during the early disease stages, and test reproducibility and external validity of pilomotor function assessment using quantitative pilomotor axon-reflex test and sudomotor function via quantitative direct and indirect test of sudomotor function. Methods/design: A prospective controlled study will be conducted at four study sites in Europe and the USA. Fifty-two male and female patients with idiopathic PD (Hoehn and Yahr 1–2) and 52 age- and sex-matched healthy controls will be recruited. Axon-reflex-mediated pilomotor erection will be induced by iontophoresis of phenylephrine on the dorsal forearm. Silicone impressions of the response will be obtained, scanned, and quantified for pilomotor muscle impressions by number, impression size, and area of axon-reflex spread. Axon-reflex-mediated sweating following acetylcholine iontophoresis will be quantified for number and size of droplets and axon-reflex spread. Sympathetic skin responses, autonomic and motor symptoms will be evaluated. Tests will be performed at baseline, after 2 weeks, 1, 2, and 3 years. Skin biopsies will be obtained at baseline and after 3 years and will be analyzed for nerve fiber density and alpha-synuclein accumulation. Discussion: We anticipate that progression of autonomic nerve dysfunction assessed via pilomotor and sudomotor axon-reflex tests is related to progression of autonomic symptom severity and alpha-synuclein deposition. Potential applications of the techniques include interventional studies evaluating disease-modifying approaches and clinical assessment of autonomic dysfunction in patients with PD.

This work deals with a design of hypokinetic dysarthria analysis system. Hypokinetic dysarthria is a speech motor dysfunction that is present in approx. 90 % of patients with Parkinson’s disease. Next there is described Parkinson's disease and change of the speech signal by this disability. The following describes the symptoms, which are used for the diagnosis of Parkinson's disease (FCR, VSA, VAI, etc.). The work is mainly focused on parameterization techniques that can be used to diagnose or monitor this disease as well as estimate its progress. A protocol of dysarthric speech acquisition is described in this work too. In combination with acoustic analysis it can be used to estimate a grade of hypokinetic dysarthria in fields of faciokinesis, phonorespiration and phonetics (correlation with 3F test). Regarding the parameterization, new features based on method RASTA. The analysis is based on parametrization sentences complicated for articulation. Experimental dataset consists of 101 PD patients with different disease progress and 53 healthy controls. For classification with feature selection have selected method mRMR.